ProKidney Corp (NASDAQ:PROK) has a beta value of 1.61 and has seen 17.53 million shares traded in the last trading session. The company, currently valued at $1.33B, closed the last trade at $4.54 per share which meant it lost -$0.64 on the day or -12.36% during that session. The PROK stock price is -57.05% off its 52-week high price of $7.13 and 89.87% above the 52-week low of $0.46. If we look at the company’s 10-day average daily trading volume, we find that it stood at 66.29 million shares traded. The 3-month trading volume is 11.37 million shares.
The consensus among analysts is that ProKidney Corp (PROK) is Buy stock at the moment, with a recommendation rating of 2.29. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 6 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.15.
ProKidney Corp (NASDAQ:PROK) trade information
Sporting -12.36% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the PROK stock price touched $4.54 or saw a rise of 36.33%. Year-to-date, ProKidney Corp shares have moved 81.60%, while the 5-day performance has seen it change 612.49%. Over the past 30 days, the shares of ProKidney Corp (NASDAQ:PROK) have changed 354.00%. Short interest in the company has seen 16.8 million shares shorted with days to cover at 32.47.
Wall Street analysts have a consensus price target for the stock at $5, which means that the shares’ value could jump 9.2% from current levels. The projected low price target is $3.0 while the price target rests at a high of $6.0. In that case, then, we find that the current price level is -32.16% off the targeted high while a plunge would see the stock lose 33.92% from current levels.
ProKidney Corp (PROK) estimates and forecasts
The company’s shares have gained 148.09% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 126.97%.
Earnings growth for 2025 is a modest 21.23% while over the next 5 years, the company’s earnings are expected to increase by 2.98%.
PROK Dividends
ProKidney Corp is expected to release its next earnings report on 2025-May-12 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
ProKidney Corp (NASDAQ:PROK)’s Major holders
Insiders own 30.05% of the company shares, while shares held by institutions stand at 41.66% with a share float percentage of 59.55%. Investors are also buoyed by the number of investors in a company, with ProKidney Corp having a total of 100.0 institutions that hold shares in the company. The top two institutional holders are MORGAN STANLEY with over 14.45 million shares worth more than $35.54 million. As of 2024-06-30, MORGAN STANLEY held 19.034% of shares outstanding.
The other major institutional holder is SUVRETTA CAPITAL MANAGEMENT, LLC, with the holding of over 9.34 million shares as of 2024-06-30. The firm’s total holdings are worth over $22.98 million and represent 12.306% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . As of Mar 31, 2025 , the former fund manager holds about 2.29% shares in the company for having 2.97 shares of worth $13.48 million while later fund manager owns 2.58 shares of worth $11.71 million as of May 31, 2025 , which makes it owner of about 1.99% of company’s outstanding stock.
